Comparative Pharmacology
Head-to-head clinical analysis: PANCURONIUM BROMIDE versus PAVULON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANCURONIUM BROMIDE versus PAVULON.
PANCURONIUM BROMIDE vs PAVULON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine from binding and thus inhibiting muscle contraction.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, blocking transmission of nerve impulses to skeletal muscle.
0.04-0.1 mg/kg IV initial bolus, then 0.01-0.02 mg/kg IV every 20-40 min as needed for neuromuscular blockade.
0.04-0.1 mg/kg IV bolus for intubation; maintenance: 0.01-0.015 mg/kg IV every 25-60 minutes as needed or continuous IV infusion: 1-2 mcg/kg/min.
None Documented
None Documented
Terminal elimination half-life: 100-120 minutes in adults with normal renal function; prolonged to 240-480 minutes in renal failure.
Terminal elimination half-life 100-120 minutes in adults with normal renal function; prolonged in renal impairment.
Renal: 50-70% unchanged; biliary/fecal: 5-10% as metabolites; minor hepatic metabolism.
Renal 80-100% as unchanged drug and metabolites; biliary/fecal negligible (<5%).
Category C
Category C
Neuromuscular Blocking Agent
Neuromuscular Blocking Agent